The company, which uses artificial intelligence to develop new treatments, now counts the venture capital firm Thrive Capital ...
Isomorphic Labs, the AI drug-discovery platform that was spun out of Google's DeepMind in 2021, has raised external capital ...
The subsidiary of Google parent Alphabet plans to use its first round of external funding to boost its ...
The London-based business – which launched in 2021 – will use the funds to further its research, expand its team and continue ...
Isomorphic Labs says it is advancing drug design programs across multiple therapeutic areas and drug modalities. These ...
AlphaFold 3, the improved version of the model used by Isomorphic Labs’ drug design engine, debuted last May. It can predict ...
Isomorphic Labs, which uses artificial intelligence technologies for drug discovery, has raised $600 million in its first ever external funding round led by Thrive Capital, the startup said on Monday.
15h
GlobalData on MSNGoogle-backed Isomorphic Labs raises $600m to advance AI drug discoveryThe funding is set to accelerate the development of Isomorphic’s AI drug design engine and advance clinical programmes.
As artificial intelligence continues to evolve, especially here in the Bay Area, one lab is working to use AI technology to ...
AI drug discovery firm Isomorphic Labs has completed the company’s first external funding round since its 2021 founding ...
Alphabet created Isomorphic Labs in 2021, spinning it out from DeepMind, the AI startup it acquired in 2014. DeepMind’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results